Final Recommendation Statement

Ocular Prophylaxis for Gonococcal Ophthalmia Neonatorum: Preventive Medication

January 29, 2019

Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Recommendation Summary

Population Recommendation Grade
Newborns The USPSTF recommends prophylactic ocular topical medication for all newborns to prevent gonococcal ophthalmia neonatorum. A

Clinician Summary

Population Newborns
Recommendation Provide prophylactic ocular topical medication to prevent gonococcal ophthalmia neonatorum.
Grade: A
Preventive Medication Erythromycin ophthalmic ointment is the only drug approved by the US Food and Drug Administration for the prophylaxis of gonococcal ophthalmia neonatorum. Ocular prophylaxis of newborns is mandated in most states and is considered standard neonatal care.
Relevant USPSTF Recommendations The USPSTF recommends screening for gonorrhea in all sexually active women 24 years and younger and in older women at increased risk for infection, as well as pregnant women.

For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, please go to http://www.uspreventiveservicestaskforce.org.

Recommendation Information

Table of Contents PDF Version and JAMA Link Archived Versions

Full Recommendation:

Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Expand All

The US Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific preventive care services for patients without obvious related signs or symptoms.

It bases its recommendations on the evidence of both the benefits and harms of the service and an assessment of the balance. The USPSTF does not consider the costs of providing a service in this assessment.

The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decision making to the specific patient or situation. Similarly, the USPSTF notes that policy and coverage decisions involve considerations in addition to the evidence of clinical benefits and harms.

Return to Table of Contents

Importance

In the United States, the rate of gonococcal ophthalmia neonatorum was an estimated 0.4 cases per 100,000 live births per year from 2013 to 2017.1-4 Gonococcal ophthalmia neonatorum can cause corneal scarring, ocular perforation, and blindness as early as 24 hours after birth.5-7 In the absence of ocular prophylaxis, transmission rates of gonococcal infection from mother to newborn are 30% to 50%.8

Reaffirmation

In 2011, the USPSTF reviewed the evidence on prophylactic ocular topical medication for all newborns to prevent gonococcal ophthalmia neonatorum and issued an A recommendation.5 The USPSTF has decided to use a reaffirmation deliberation process to update this recommendation. The USPSTF uses the reaffirmation process for well-established, evidence-based standards of practice in current primary care practice for which only a very high level of evidence would justify a change in the grade of the recommendation.9 In its deliberation of the evidence, the USPSTF considers whether the new evidence is of sufficient strength and quality to change its previous conclusions about the evidence.

Benefits of Preventive Medication

The USPSTF found convincing evidence that ocular prophylaxis of newborns with 0.5% erythromycin ophthalmic ointment can prevent gonococcal ophthalmia neonatorum.

Harms of Preventive Medication

The USPSTF found convincing evidence that ocular prophylaxis of newborns with 0.5% erythromycin ophthalmic ointment is not associated with serious harms.

USPSTF Assessment

Using a reaffirmation process,9 the USPSTF concludes with high certainty that the net benefit of topical ocular prophylaxis of all newborns to prevent gonococcal ophthalmia neonatorum is substantial.

Return to Table of Contents

Patient Population Under Consideration

This recommendation applies to all newborns regardless of gestational age.

Preventive Medication

Erythromycin ophthalmic ointment is considered effective in preventing gonococcal ophthalmia neonatorum.10 Other medications, such as tetracycline ophthalmic ointment and silver nitrate, have been evaluated for the prevention of gonococcal ophthalmia neonatorum but are no longer available in the United States.3 Gentamicin was used during a period of erythromycin shortage, although its use was associated with ocular reactions (chemical conjunctivitis).11 Povidone-iodine has been proposed for prophylaxis, but there are limited data on its benefits and harms.3 Currently, erythromycin is the only drug approved by the US Food and Drug Administration for the prophylaxis of gonococcal ophthalmia neonatorum.11 Ocular prophylaxis of newborns is mandated in most states6 and is considered standard neonatal care.11

Additional Approaches to Prevention

The rates of gonococcal ophthalmia neonatorum are related to gonococcal infection rates in women of reproductive age.3 Accordingly, screening for and treatment of gonococcal infection in pregnant women is an important strategy for reducing the sexual transmission of gonorrhea and subsequent vertical transmission leading to gonococcal ophthalmia neonatorum. While screening and treatment programs have reduced the rates of gonorrhea in pregnant women, there are large disparities in access to prenatal care in the United States.1,12 Risk-based prophylaxis has also been proposed as an alternative strategy for preventing gonococcal ophthalmia neonatorum. Currently, there are no risk-based tools for screening pregnant women and no studies examining the use of risk-based vs universal prophylaxis. Therefore, ocular prophylaxis remains an important tool in the prevention of gonococcal ophthalmia neonatorum.

Useful Resources

The USPSTF recommends screening for gonorrhea in all sexually active women 24 years and younger and in older women at increased risk for infection, as well as pregnant women.13 The Centers for Disease Control and Prevention provides clinical guidance for ocular prophylaxis and treatment of gonococcal ophthalmia neonatorum.10

Return to Table of Contents

Research Needs and Gaps

The only available drug approved by the US Food and Drug Administration for the prevention of gonococcal ophthalmia neonatorum is 0.5% erythromycin ophthalmic ointment. It is currently unknown whether Neisseria gonorrhoeae has developed resistance to erythromycin ointment in the United States. However, given increased antimicrobial resistance noted in other countries, further research is needed to find safe and effective alternatives to erythromycin. Another area for research is whether risk-based prophylaxis of newborns, based on maternal risk factors, is as effective as universal prophylaxis.

Return to Table of Contents

Burden of Disease

Ophthalmia neonatorum is conjunctivitis occurring in infants during the first month of life. Gonococcal ophthalmia neonatorum occurs when gonococcal infection is transmitted to newborns during delivery by women infected with N gonorrhoeae.10 The rates of gonococcal conjunctivitis in infants are directly related to the rates of gonorrhea among women of reproductive age.3 In the United States, adolescents and young adult women have the highest rates of gonorrhea, with rates peaking at age 19 years (872.2 cases per 100,000 women); among women aged 20 to 24 years, there were 648.8 cases per 100,000 women in 2017.1 Estimated rates of gonorrhea among pregnant women in the US primary care setting are not available. Although gonococcal infection rates have declined since national screening programs were implemented in the 1970s, reported gonorrhea cases have increased recently, from 105.3 cases to 171.9 cases per 100,000 population from 2013 to 2017, respectively.1 An estimated 6.2% of births in the United States occur among women receiving little to no prenatal care, although rates as high as 20% have been documented in certain populations based on location and race/ethnicity.12

Data based on infant age (younger than 1 year) and specimen source (conjunctiva or eye) indicate there were an estimated 42 infections (≤0.4 cases) per 100,000 live births per year from 2013 to 2017.1 However, limitations in reporting suggest this is an underestimate.14 Using a broader definition that includes cases with unknown, other, or missing specimen sources, the prevalence of gonococcal ophthalmia neonatorum during that period could possibly be higher.3

Untreated gonococcal ophthalmia neonatorum can result in severe and lasting conditions, including corneal scarring, ocular perforation, and blindness.7 There are no contemporary estimates of blindness related to gonococcal ophthalmia neonatorum in the United States. Historical estimates from 19th-century Europe show that gonococcal ophthalmia neonatorum was a major cause of childhood blindness, resulting in corneal damage in 20% of infected infants and blindness in 3%.15, 16 An observational study from Nairobi, Kenya, in the 1980s reported that 16% of a series of 64 infants with gonococcal ophthalmia neonatorum had corneal involvement.17

Scope of Review

To reaffirm its 2011 recommendation on ocular prophylaxis for gonococcal ophthalmia neonatorum,5 the USPSTF commissioned a targeted evidence review.3 ,4 The aim of this review was to identify substantial new evidence that was sufficient to change the prior recommendation.

Benefits of Preventive Medication

Previous USPSTF reviews found convincing evidence that topical ocular prophylaxis can prevent gonococcal ophthalmia neonatorum. The USPSTF found no new data that would change its previous conclusion that topical ocular prophylaxis is effective in preventing gonococcal ophthalmia neonatorum and related ocular conditions.

Potential Harms of Preventive Medication

The USPSTF found no new data that would change its previous conclusion that there is convincing evidence that topical ocular prophylaxis of all newborns is not associated with serious harms. Possible harms include the potential for antimicrobial resistance to treatment medication.

Estimate of Magnitude of Net Benefit

The USPSTF considered the evidence using a reaffirmation process and found that topical ocular prophylaxis is effective in preventing gonococcal ophthalmia neonatorum and related ocular conditions, with small associated harms and substantial benefit. Therefore, the USPSTF reaffirms its previous conclusion that there is convincing evidence that topical ocular prophylaxis for all newborns provides substantial benefit.

Response to Public Comment

A draft version of this recommendation statement was posted for public comment on the USPSTF website from September 11 to October 9, 2018. Several comments questioned the continued need for universal prophylaxis given the relative low rate of disease. The USPSTF reaffirmed its recommendation based on several factors, including the rapid course and serious adverse effects of infection, increasing rates of gonococcal infection, and the large number of persons who do not receive screening for gonococcal infection during pregnancy in the United States. Comments also supported risk-based prophylaxis as an alternative strategy for prevention. However, there are no tools for assessing the risk of infection in newborns and no studies examining the use of risk-based vs universal prophylaxis. The USPSTF revised the recommendation to clarify this point. In addition, a number of comments promoted the use of iodine solutions (povidone-iodine) as an alternative to erythromycin ophthalmic ointment. The evidence review found limited studies on the use of iodine solutions and notes that they are not approved for use in the United States as ocular prophylaxis for gonococcal ophthalmia neonatorum. The USPSTF added language to address this concern.

Return to Table of Contents
Return to Table of Contents

The Centers for Disease Control and Prevention, American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and the World Health Organization all recommend universal topical ocular prophylaxis to prevent gonococcal ophthalmia neonatorum.1,20,21 The Canadian Pediatric Society recommends against universal prophylaxis. Several European countries, including Denmark, Norway, Sweden, and the United Kingdom, no longer require universal prophylaxis, instead opting for a prevention strategy of increased screening and treatment of pregnant women.22 In 2017, the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists recommended screening all pregnant women at risk for gonorrhea or who live in a high-prevalence area at the first prenatal visit; women with gonococcal infection should be retested in 3 to 6 months, preferably in the third trimester. In addition, if the result of the first test is negative but the woman is at high risk for gonorrhea, retesting at the beginning of the third trimester is recommended.20

Return to Table of Contents

The US Preventive Services Task Force (USPSTF) members include the following individuals: Susan J. Curry, PhD (University of Iowa, Iowa City); Alex H. Krist, MD, MPH (Fairfax Family Practice Residency, Fairfax, Virginia, and Virginia Commonwealth University, Richmond); Douglas K. Owens, MD, MS (Veterans Affairs Palo Alto Health Care System, Palo Alto, California, and Stanford University, Stanford, California); Michael J. Barry, MD (Harvard Medical School, Boston, Massachusetts); Aaron B. Caughey, MD, PhD (Oregon Health & Science University, Portland); Karina W. Davidson, PhD, MASc (Columbia University, New York, New York); Chyke A. Doubeni, MD, MPH (University of Pennsylvania, Philadelphia); John W. Epling Jr, MD, MSEd (Virginia Tech Carilion School of Medicine, Roanoke); Alex R. Kemper, MD, MPH, MS (Nationwide Children’s Hospital, Columbus, Ohio); David C. Grossman, MD, MPH (Kaiser Permanente Washington Health Research Institute, Seattle); Martha Kubik, PhD, RN (Temple University, Philadelphia, Pennsylvania); C. Seth Landefeld, MD (University of Alabama at Birmingham); Carol M. Mangione, MD, MSPH (University of California, Los Angeles); Michael Silverstein, MD, MPH (Boston University, Boston, Massachusetts); Melissa A. Simon, MD, MPH (Northwestern University, Evanston, Illinois); Chien-Wen Tseng, MD, MPH, MSEE (University of Hawaii, Honolulu, and Pacific Health Research and Education Institute, Honolulu, Hawaii); John B. Wong, MD (Tufts University School of Medicine, Boston, Massachusetts).

Return to Table of Contents
Return to Table of Contents

1. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2017. CDC website. https://www.cdc.gov/std/stats17/default.htm. Updated October 15, 2018. Accessed December 3, 2018.
2. Kreisel K, Weston E, Braxton J, Llata E, Torrone E. Keeping an eye on chlamydia and gonorrhea conjunctivitis in infants in the United States, 2010-2015. Sex Transm Dis. 2017;44(6):356-358.
3. Guirguis-Blake JM, Evans CV, Rushkin M. Ocular Prophylaxis for Gonococcal Ophthalmia Neonatorum: A Reaffirmation Evidence Update for the U.S. Preventive Service Task Force. Evidence Synthesis No. 173. AHRQ Publication No. 18-05244-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2019.
4. Guirguis-Blake JM, Evans CV, Rushkin M. Ocular prophylaxis for gonococcal ophthalmia neonatorum: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2019;321(4):404-406.
5. U.S. Preventive Services Task Force. Ocular Prophylaxis for Gonococcal Ophthalmia Neonatorum: U.S. Preventive Services Task Force Reaffirmation Recommendation Statement. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
6. Snowe RJ, Wilfert CM. Epidemic reappearance of gonococcal ophthalmia neonatorum. Pediatrics. 1973;51(1):110-114.
7. Woods CR. Gonococcal infections in neonates and young children. Semin Pediatr Infect Dis. 2005;16(4):258-270.
8. Laga M, Meheus A, Piot P. Epidemiology and control of gonococcal ophthalmia neonatorum. Bull World Health Organ. 1989;67(5):471-477.
9. U.S. Preventive Services Task Force. U.S. Preventive Services Task Force Procedure Manual. https://www.uspreventiveservicestaskforce.org/Page/Name/procedure-manual. Accessed December 3, 2018.
10. Centers for Disease Control and Prevention (CDC). 2015 sexually transmitted diseases treatment guidelines. CDC website. https://www.cdc.gov/std/tg2015/default.htm. Updated January 25, 2017. Accessed December 3, 2018.
11. Hammerschlag MR. Chlamydial and gonococcal infections in infants and children. Clin Infect Dis. 2011;53(Suppl 3):S99-102.
12. Martin JA, Hamilton BE, Osterman MJ. Births in the United States, 2016. NCHS Data Brief. 2017;(287):1-8.
13. U.S. Preventive Services Task Force. Screening for chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161(12):902-910.
14. Pilling R, Long V, Hobson R, Schweiger M. Ophthalmia neonatorum: a vanishing disease or underreported notification? Eye (Lond). 2009;23(9):1879-1880.
15. Schaller UC, Klauss V. Is Credé's prophylaxis for ophthalmia neonatorum still valid? Bull World Health Organ. 2001;79(3):262-263.
16. Stephenson S. Ophthalmia Neonatorum With Especial Reference to Its Causation and Prevention. London: George Pulman, Ophthalmoscope Press; 1907.
17. Fransen L, Nsanze H, Klauss V, et al. Ophthalmia neonatorum in Nairobi, Kenya: the roles of Neisseria gonorrhoeae and Chlamydia trachomatis. J Infect Dis. 1986;153(5):862-869.
18. U.S. Preventive Services Task Force. Screening for gonorrhea - including ocular prophylaxis in newborns. In: Guide to Clinical Preventive Services: Report of the U.S. Preventive Services Task Force. 2nd ed. Baltimore, MD: Williams & Wilkins; 1996.
19. U.S. Preventive Services Task Force. Screening for gonorrhea: recommendation statement. Ann Fam Med. 2005;3(3):263-267.
20. American Academy of Pediatrics, American College of Obstetricians and Gynecologists. Guidelines for Perinatal Care. 8th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2017.
21. World Health Organization. WHO Guidelines for the Treatment of Neisseria gonorrhoeae. Geneva: World Health Organization; 2016.
22. Moore DL, MacDonald NE; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Preventing ophthalmia neonatorum. Paediatr Child Health. 2015;20(2):93-96.

Return to Table of Contents